Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT trial of eribulin with or without endocrine therapy in luminal metastatic breast cancer
2017-004324-30Phase 2Terminated
- Sponsor
- MEDSIR
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eribulin in breast cancer (2 arms), sponsored by MEDSIR. Primary endpoint: Overall response rate. Started Nov 2018; status: terminated.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-004324-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004324-30.